357262-60-3

Basic information

• Product Name: 2-[(2R)-2-methyl-4-(phenylcarbonyl)piperazin-1-yl]-2-oxo-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone
• Synonyms: 1,2-ethanedione, 1-[(2R)-4-benzoyl-2-methyl-1-piperazinyl]-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-; 1-[(2R)-4-benzoyl-2-methylpiperazin-1-yl]-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione
• CAS NO: 357262-60-3
• Molecular Formula: C₂₁H₂₀N₄O₃
• Molecular Weight: 376.4085
• Mol File: 357262-60-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 622.1°C at 760 mmHg
• Flash Point: 330°C
• Density: 1.335g/cm³
• Vapor Pressure: 2.13E-15mmHg at 25°C
• Refractive Index: 1.663
• CAS DataBase Reference: 2-[(2R)-2-methyl-4-(phenylcarbonyl)piperazin-1-yl]-2-oxo-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(2R)-2-methyl-4-(phenylcarbonyl)piperazin-1-yl]-2-oxo-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone(357262-60-3)
• EPA Substance Registry System: 2-[(2R)-2-methyl-4-(phenylcarbonyl)piperazin-1-yl]-2-oxo-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone(357262-60-3)

Safety Data

• Hazardous Substances Data: 357262-60-3(Hazardous Substances Data)

Upstream product

• 357263-39-9 1-benzoyl-3-(R)-methylpiperazine 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 357263-49-1 methyl α-oxo-1H-pyrrolo[2,3-b]pyridine-3-acetate 
• 75336-86-6 (2R)-methylpiperazine 
• 271-63-6 7-Azaindole 
• 93-58-3 benzoic acid methyl ester 

Downstream Products

• 357262-96-5 4-benzoyl-2-(R)-methyl-1-[(4-nitro-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]piperazine 
• 357263-05-9 4-benzoyl-1-[(4-methoxy-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine 
• 357263-13-9 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine 
• 357262-90-9 4-benzoyl-2-(R)-methyl-1-[(7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]piperazine 

Relevant articles and documents

TARGETED BIFUNCTIONAL DEGRADERS

The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

Prodrugs of piperazine and substituted piperidine antiviral agents

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

Antiviral azaindole derivatives

The present invention is directed to a series of chemical entities that express HIV-1 inhibitory activities.